Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$7.03	$7.86	$5.85 ▼ $24.17	$199.81M	2.43	446,105 shs	266,400 shs
BLUE bluebird bio	$4.97	$4.78	$3.20 ▼ $5.03	$48.67M	0.27	807,956 shs	N/A
CSLLY CSL	$17.69	$22.75	$17.06 ▼ $44.86	$33.89B	0.69	405,564 shs	363,251 shs
NVS Novartis	$152.14 +0.1%	$150.02	$111.06 ▼ $170.46	$290.31B	0.46	1.35 million shs	1.41 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	-5.89%	-18.16%	-8.34%	-42.38%
BLUE bluebird bio	0.00%	0.00%	0.00%	0.00%	-0.40%
CSLLY CSL	0.00%	+1.61%	-23.59%	-66.05%	-77.82%
NVS Novartis	0.00%	+2.80%	+4.67%	-7.57%	+34.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$7.03	$7.86	$5.85 ▼ $24.17	$199.81M	2.43	446,105 shs	266,400 shs
BLUE bluebird bio	$4.97	$4.78	$3.20 ▼ $5.03	$48.67M	0.27	807,956 shs	N/A
CSLLY CSL	$17.69	$22.75	$17.06 ▼ $44.86	$33.89B	0.69	405,564 shs	363,251 shs
NVS Novartis	$152.14 +0.1%	$150.02	$111.06 ▼ $170.46	$290.31B	0.46	1.35 million shs	1.41 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	-5.89%	-18.16%	-8.34%	-42.38%
BLUE bluebird bio	0.00%	0.00%	0.00%	0.00%	-0.40%
CSLLY CSL	0.00%	+1.61%	-23.59%	-66.05%	-77.82%
NVS Novartis	0.00%	+2.80%	+4.67%	-7.57%	+34.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.67	Moderate Buy	$25.44	261.94% Upside
BLUE bluebird bio	0.00	N/A	N/A	N/A
CSLLY CSL	1.75	Reduce	N/A	N/A
NVS Novartis	2.31	Hold	$141.20	-7.19% Downside

Current Analyst Ratings Breakdown

Latest CSLLY, NVS, BLUE, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/11/2026	CSLLY CSL	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/11/2026	CSLLY CSL	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
5/11/2026	CSLLY CSL	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/29/2026	NVS Novartis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (A-) ➝ Buy (B)
4/21/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
3/26/2026	NVS Novartis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$143.00 ➝ $170.00
3/19/2026	NVS Novartis	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
3/18/2026	ARCT Arcturus Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$22.00
3/17/2026	ARCT Arcturus Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
3/11/2026	NVS Novartis	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$180.00
3/5/2026	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$66.00 ➝ $21.00

(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$42.35M	4.72	N/A	N/A	$6.73 per share	1.04
BLUE bluebird bio	$103.95M	0.47	N/A	N/A	$35.59 per share	0.14
CSLLY CSL	$15.56B	2.18	$2.19 per share	8.09	$11.05 per share	1.60
NVS Novartis	$54.53B	5.32	$10.75 per share	14.15	$20.40 per share	7.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$2.81	N/A	N/A	N/A	-143.80%	-36.55%	-28.40%	8/10/2026 (Estimated)
BLUE bluebird bio	-$211.91M	-$41.32	N/A	N/A	N/A	-565.74%	-322.46%	-53.17%	N/A
CSLLY CSL	$3.00B	N/A	N/A	10.41	3.15	N/A	N/A	N/A	N/A
NVS Novartis	$13.98B	$6.98	21.80	15.48	2.67	24.87%	38.82%	15.16%	7/21/2026 (Estimated)

Latest CSLLY, NVS, BLUE, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	ARCT Arcturus Therapeutics	-$1.0320	-$0.95	+$0.0820	-$0.95	$6.30 million	$2.06 million
4/27/2026	Q1 2026	NVS Novartis	$2.11	$1.99	-$0.12	$1.65	$13.44 billion	$13.52 billion
3/3/2026	Q4 2025	ARCT Arcturus Therapeutics	-$0.92	-$1.03	-$0.11	-$1.0230	$14.32 million	$7.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	10.17%	N/A	N/A	N/A
BLUE bluebird bio	N/A	N/A	N/A	N/A	N/A
CSLLY CSL	$0.59	3.34%	N/A	N/A	N/A
NVS Novartis	$3.08	2.02%	+5.28%	44.13%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	6.31	6.31
BLUE bluebird bio	0.37	0.51	0.33
CSLLY CSL	0.51	2.57	1.15
NVS Novartis	0.96	0.85	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
BLUE bluebird bio	87.43%
CSLLY CSL	0.03%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
BLUE bluebird bio	1.40%
CSLLY CSL	N/A
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
BLUE bluebird bio	520	9.79 million	9.59 million	Optionable
CSLLY CSL	29,904	1.92 billion	N/A	Not Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable

CSLLY, NVS, BLUE, and ARCT Headlines

Recent News About These Companies

Novartis (NVS) Positioned for Growth Through Transformative Innovations

May 21, 2026 | finance.yahoo.com

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

May 21, 2026 | globenewswire.com

Cancer Stocks That Are Advancing the Future of Oncology Care

May 18, 2026 | zacks.com

US Supreme Court rebuffs pharma challenge to Biden-era drug price

May 18, 2026 | reuters.com

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade (NVS)

...

May 18, 2026 | marketbeat.com

Novartis International AG: Novartis tender offer for Advanced Accelerator Applications commences

May 16, 2026 | finanznachrichten.de

Implied Volatility Surging for Novartis Stock Options

May 13, 2026 | zacks.com

Novartis breaks ground on US radioligand therapy site

May 12, 2026 | pmlive.comP

Novartis AG (NVS) Expands U.S. Manufacturing Footprint with New Texas Site

May 11, 2026 | insidermonkey.com

Q2 Earnings Forecast for Novartis Issued By Zacks Research

May 11, 2026 | marketbeat.com

NewEdge Wealth LLC Has $69.67 Million Stock Position in Novartis AG $NVS

May 10, 2026 | marketbeat.com

Novartis AG (NYSE:NVS) Receives Average Recommendation of "Hold" from Brokerages

May 10, 2026 | marketbeat.com

FY2027 EPS Estimates for Novartis Lifted by Erste Group Bank

May 8, 2026 | marketbeat.com

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

May 7, 2026 | globenewswire.com

This small biotech — taking on AbbVie, Novartis and Sanofi — just catapulted into a breakout

May 6, 2026 | msn.com

Principal Financial Group Inc. Reduces Holdings in Novartis AG $NVS

May 6, 2026 | marketbeat.com

New Bill: Representative Kathy Castor introduces H.R. 8651: Advancing Safe Medications for Moms and Babies Act of 2026

May 5, 2026 | quiverquant.comQ

Novartis to cut 220 jobs as it closes German site

May 5, 2026 | reuters.com

QRG Capital Management Inc. Boosts Stock Holdings in Novartis AG $NVS

May 5, 2026 | marketbeat.com

Novartis AG $NVS Shares Purchased by Truist Financial Corp

May 5, 2026 | marketbeat.com

Triasima Portfolio Management inc. Acquires 32,620 Shares of Novartis AG $NVS

May 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CSLLY, NVS, BLUE, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$7.03 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$7.10 +0.08 (+1.07%)

As of 05/22/2026 07:51 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

bluebird bio NASDAQ:BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

CSL OTCMKTS:CSLLY

$17.69 0.00 (0.00%)

As of 05/22/2026 04:00 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Novartis NYSE:NVS

$152.14 +0.13 (+0.09%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$152.00 -0.14 (-0.09%)

As of 05/22/2026 07:58 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CSLLY, NVS, BLUE, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CSLLY, NVS, BLUE, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CSLLY, NVS, BLUE, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CSLLY, NVS, BLUE, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

bluebird bio NASDAQ:BLUE

CSL OTCMKTS:CSLLY

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CSLLY, NVS, BLUE, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CSLLY, NVS, BLUE, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CSLLY, NVS, BLUE, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CSLLY, NVS, BLUE, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

bluebird bio NASDAQ:BLUE

CSL OTCMKTS:CSLLY

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools